Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat + HMPL-689 in relapsed/refractory lymphoma
CTR20223063Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tazemetostat, amdizatinib in lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), peripheral T-cell lymphoma (PTCL), sponsored by HUTCHMED. Started Dec 2022; status: completed.
02
Drugs
tazemetostatamdizatinib
03
Conditions
lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20223063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223063.